3/6 Patients' tumors or circulating tumor DNA were analyzed by NGS. The median progression-free survival was 4.2 months, the median overall survival was 9.6 months, and the overall response rate was 17.5%. #GU21@MCR_AACR@oalhalabimd#bcsmbit.ly/3d25A1U
1/10 COVID19 & Cancer👉Several studies now provide insights into the enigma surrounding the determinants of COVID-19 & cancer 👉A global effort to understand the riddles of COVID-19 and cancer @NatureCancer@COVID19nCCC@OncoAlertnature.com/articles/s4301…
🚨⭐️ By popular demand 👉The Top 10 clinical publications in Oncology in 2020 (In no particular order). Some important papers bundled + Additional 5 more papers representing major advances in the field @OncoAlert
1. Pembrolizumab led to significantly longer progression-free survival vs chemotherapy as first-line therapy for MSI-H–dMMR metastatic colorectal cancer 👉Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer @NEJM@agrotheynejm.org/doi/full/10.10…
2. Most children with neurofibromatosis type 1 and inoperable plexiform neurofibromas had durable tumor shrinkage and clinical benefit from selumetinib 👉Selumetinib in Children with Inoperable Plexiform Neurofibromas @NEJMnejm.org/doi/full/10.10…
# 2The Master Observational Trial (MOT)-->Patients are broadly accepted into the trial along with diagnosis + staging info. Biomarker testing results (both positive and negative) are collected & classified using methods shown in Figures 1A and 1B.
# 3High-level outcomes are collected in connection with each line of therapy. All of the information is tied together in a prospective observational registry using standardized reporting methods and metrics. cell.com/cell/fulltext/…
Presenting the GLOBAL Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of Selpercatinib #LOXO-292 in Patients with #RET + NSCLC !Thank you to all the patients and caregivers ! Huge win for RET + #NSCLC patients #precisionmedicine#LCSM#endcancer
RET Fusions are bonafide #lung cancer drivers #LSCM